Can you recall the specific cancer type for keytruda's first fda approval?

What cancer type was Keytruda’s first FDA approval for?

Keytruda’s first FDA approval (in 2014) was for unresectable or metastatic melanoma that had progressed after treatment with ipilimumab (Yervoy) and, if it was BRAF V600 mutation–positive, a BRAF inhibitor [1].

Was it approved for other cancers at the same time?

No. That first approval was specifically for the melanoma indication described above. Keytruda was later approved for additional cancers as new clinical data were reviewed by the FDA [1].

When was that approval granted?

The initial FDA approval for Keytruda was granted in 2014 [1].

Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-c-der?searchapifulltext=Keytruda%20unresectable%20metastatic%20melanoma%20ipilimumab%20BRAF%20inhibitor